Site Search
Professionals 700 results
Capabilities 85 results
Practice Area
Our Patent Litigation Practice is one of the country’s most active and highly regarded. Our seasoned patent litigators bring extensive courtroom experience to every matter we handle. According to Lex Machina, we are among the top three national patent defense firms in the country for number of appearances and cases filed, and we also were the top national defense firm for number of patent trials in the last five years (2018–2022).
Practice Area
The United States International Trade Commission (ITC) is an increasingly popular venue for patent infringement litigation. More and more companies are seeking to halt importations of infringing products into the United States by turning to the ITC for expedited relief. Section 337 investigations conducted by the ITC provide complainants with a “fast track” to remedy IP matters that typically go to trial within 10 months. Since many Section 337 cases go to trial, selecting an ITC litigation team with a command of the technology, patent law, and specialized procedural practice is extremely important. We have handled more than 100 cases before the ITC.
Practice Area
Winston’s Intellectual Property (IP) Practice is one of the most active and highly regarded in the United States per Chambers USA, Benchmark Litigation US, and Best Law Firms®, among other ranking organizations. Our team features some of the country’s best IP lawyers, attorneys with the technical abilities to litigate and try highly complex IP disputes, and technical lawyers who provide critical advisory services.
Experience 85 results
Experience
|August 18, 2025
Winston Represented Amphenol in Definitive Agreement to Acquire Trexon
Winston represented Amphenol Corporation (NYSE: APH), one of the world’s largest designers, manufacturers, and marketers of electrical, electronic, and fiber optic connectors and systems, as well as coaxial and high-speed specialty cables, in its definitive agreement to acquire Trexon, a leading provider of high-reliability interconnect and cable assemblies primarily serving the defense market. The acquisition is valued at approximately US$1B, subject to customary post-closing adjustments. Amphenol will finance the transaction with cash on hand and expects to close in the fourth quarter of 2025.
Experience
|July 30, 2025
Represent Norman W. Fries, Inc. d/b/a Claxton Poultry Farms in a series of 15+ antitrust class actions consolidated in the Northern District of Illinois and brought by plaintiffs who allege that Claxton and the nation’s other largest poultry producers conspired to fix the price of broiler chickens in a scheme from 2008 to 2016 that raised the price for broiler chickens by artificially reducing supply.
Experience
|July 9, 2025
BitMine Completes $20 Billion Upsize of ATM Program
Winston & Strawn LLP represented BitMine Immersion Technologies, Inc. in connection with its latest expansion of its at-the-market (ATM) equity offering, increasing the program by $20 billion to a total of $24.5 billion. BitMine (NYSE: BMNR), a former bitcoin mining company now focused on building the largest Ethereum treasury in the world, currently holds more than 1,713,899 ETH valued at over $8.2 billion.
Insights & News 3,381 results
Sponsorship
|October 15, 2025
Winston & Strawn Sponsors ChIPs 2025 Global Summit
Winston & Strawn is a proud sponsor of the 2025 ChIPs Global Summit, which brings together women from all over the world working in technology, policy, private practice, corporations, government, academia, and beyond. Each year, the summit aims to advance innovation through diversity of thought and connect women through engagement opportunities.
Client Alert
|October 3, 2025
|4 Min Read
Debanking Developments: New Regulatory Scrutiny Coming After Trump Executive Order
In this alert, Winston’s Financial Services Industry Group examines the latest developments in regulatory scrutiny of “debanking,” with a particular focus on recent actions following a Trump administration executive order.
In the Media
|October 1, 2025
|1 Min Read
Richard Semple Joins Winston & Strawn in London
Winston & Strawn recently announced the appointment of finance specialist Richard Semple as a partner in the Transactions Department in the London office. Richard brings extensive experience advising sponsor, borrower, and lender clients on real estate finance transactions across the UK and European markets. His practice covers all aspects and all stages of domestic and cross-border real estate finance matters.
Other Results 61 results
Law Glossary
Colloquially referred to as the “patent dance,” the BPCIA provides a framework that includes certain steps and a schedule during which the applicant and reference product sponsor exchange confidential information disclosed in the aBLA. During the patent dance, the applicant and sponsor identify the patents that could be litigated in the future during two potential phases of litigation. In the first phase, the sponsor can allege infringement of a subset of the patents identified during the patent dance. The second phase begins after the sponsor receives the Notice of Commercial Marketing from the applicant. During this second phase, the sponsor can assert any remaining patents that were not asserted in the first phase.
Law Glossary
What Is the Patent Trial and Appeal Board?
The Patent Trial and Appeal Board (PTAB) is a tribunal within U.S. Patent and Trademark Office. The PTAB oversees trial proceedings, namely: inter partes review (IPR), post-grant review (PGR), covered business method (CBM) review, and derivation proceedings. The Board also hears appeals from adverse patentability decisions by patent examiners in original applications, reissues, and reexaminations. And, while phasing out since the passage of the America Invents Act (AIA) in 2011, the PTAB is also responsible for deciding interferences. The PTAB was previously referred to as the Board of Patent Appeals and Interferences and was renamed by the AIA.
Law Glossary
What Are the Patent Litigation Differences Between the BPCIA and Hatch-Waxman Act?
There are fundamental differences between the abbreviated approval processes to obtain FDA approval for biosimilars and generic drugs as those processes relate to patent litigation.